Download this eBook and leverage the momentum gained from the
62nd ASH Annual Meeting. Stay ahead of the rapidly evolving landscape in
CAR T-cell therapy for hematological malignancies.
The successful development of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies for select B-cell malignancies is one of the most remarkable therapeutic advances in the past decade. In recent years, research in the field of CAR T-cell therapies has intensified. This eBook explores the new targets and approaches that may increase efficacy, decrease toxicity and expand access to these treatments.
In this new eBook we explore: